BitFrontier Capital Holdings, Inc. (OTCID: BFCH), doing business as UNLOCKD, Inc., announced plans to amend its Regulation A offering to increase the price of its common stock from $0.0001 to $0.001 per share, according to a release distributed through NEWMEDIAWIRE. The proposed tenfold increase would mean the company issues 90% fewer shares to raise an equivalent amount of gross equity capital, a change management says would reduce potential shareholder dilution and preserve authorized share capacity for future strategic initiatives.
The significance lies in how the company finances its next phase. At the existing offering price, raising $100,000 in gross proceeds would require issuing roughly 1 billion common shares; at the proposed price, the same amount would require approximately 100 million shares. For a small-cap company with a limited authorized share structure and anticipated capital needs tied to acquisitions, product development and commercialization, that difference could shape how much room remains for future deals.
The original offering price was set during an earlier stage of restructuring, when access to capital was limited and management focused on stabilizing the business and addressing legacy obligations. Since then, UNLOCKD has completed acquisitions involving EVERMIND, Ancient Extracts USA and the 1ENERGY consumer brand assets. Ancient Extracts USA is the company's current revenue-generating operating brand, while EVERMIND and 1ENERGY provide intellectual property and potential commercialization platforms. UNLOCKD also announced a binding letter of intent to acquire Ancient Extracts UK, which based on previously announced operating figures could add nearly $1 million in annualized revenue upon closing, subject to financing, due diligence, audit requirements, definitive documentation and other closing conditions.
"We believe the Company is in a materially different position today than when we established the original offering price," said John P. Gorst, Chief Executive Officer of UNLOCKD, adding that continuing to issue equity at the original price is no longer appropriate for the company's direction. Gorst said management cannot control the market price but can control the terms on which it is willing to issue new equity.
The company intends to file the necessary amendment with the U.S. Securities and Exchange Commission, and implementation remains subject to applicable filing, qualification and securities-law requirements. The proposed offering price is a management-determined financing term, not an independent valuation or an indication of expected trading price, and the ability to raise capital at that price depends on investor demand and market conditions. Investors are directed to the company's offering circular and risk factors available through the SEC's EDGAR database at www.sec.gov, and further details on the release are available through www.newmediawire.com.
For readers and investors in microcap consumer-health names, the announcement signals a shift toward more disciplined capital formation and an emphasis on operating execution, revenue growth and commercialization of acquired assets, though the company cautions that future equity issuances may still dilute existing shareholders and that there can be no assurance the amendment will be qualified or implemented.
